Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETBX-021 in HER2-low breast cancer
NCT02751528Phase 1Terminated
- Sponsor
- NantBioScience
- Start
- Mar 2017
- Primary completion
- Aug 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ETBX-021 in breast cancer, sponsored by NantBioScience. Primary endpoints: Treatment-emergent Adverse Events up to 12 months, Treatment Emergent Serious Adverse Events up to 12 months and 2 more. Started Mar 2017; status: terminated.
02
Drugs
ETBX-021
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02751528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751528.